Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies.
Voriconazole has been shown to be safe and effective for fungal infection. However, its population pharmacokinetics for patients with hematological malignancies remains unknown. We performed a population pharmacokinetics study of nine hematological patients with 36 points samples. We approximated the drug concentration curve using a linear one-compartment model. The distribution of volume (Vd), elimination rate constant, and clearance (CL) were 68.7 L, 0.163 h(-1), and 11.2 L/h, respectively. By coincidence, our study has verified that the current administration is enough to treat fungus infections by using Monte Carlo simulation. Our data demonstrated that the current administration method is appropriate and effective. Our results may prove to be useful as a basic reference for the clinical usage of voriconazole.
Nomura
K
K
Department of Hematology and Oncology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kamigyo-ku, Kyoto, Japan. nomuken@koto.kpu-m.ac.jp
Fujimoto
Y
Y
Kanbayashi
Y
Y
Ikawa
K
K
Taniwaki
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D044466:Asian People; D005260:Female; D019337:Hematologic Neoplasms; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009010:Monte Carlo Method; D009181:Mycoses / Q000188:drug therapy; D011743:Pyrimidines / Q000493:pharmacokinetics* / Q000494:pharmacology; D014018:Tissue Distribution; D014230:Triazoles / Q000493:pharmacokinetics* / Q000494:pharmacology; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole